PGR and breast cancer: The clinical efficacy of lonaprisan, a type III PR antagonist that promotes PR repression through the recruitment of transcriptional co-repressors (while maintaining DNA binding), was measured in a phase II study as second-line therapy for PR-positive breast cancer [70].